Impacto da atenção farmacêutica na qualidade de vida e no perfil clínico de pacientes com hipertensão arterial assistidos pela estratégia saúde de família

• Ano de defesa: 2013
• Autor(a) principal: Aquino, Aline Teixeira de
• Orientador(a): Amaral, Rita Goreti
• Banca de defesa: Amaral, Rita Goreti, Garrote, Clévia Ferreira Duarte, Zampieri , Ana Lúcia Teixeira de Carvalho
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• dARK ID: ark:/38995/0013000006b06
• Idioma: por
• Instituição de defesa: Universidade Federal de Goiás
• Programa de Pós-Graduação: Programa de Pós-graduação em Ciências da Saúde (FM)
• Departamento: Faculdade de Medicina - FM (RG)
• País: Brasil
• Palavras-chave em Português: Atenção farmacêutica; Hipertensão arterial; Adesão à medicação; Qualidade de vida
• Palavras-chave em Inglês: Pharmaceutical care; Hypertension; Medication adherence; Quality of life
• Área do conhecimento CNPq: MEDICINA::ANATOMIA PATOLOGICA E PATOLOGIA CLINICA
• Link de acesso: http://repositorio.bc.ufg.br/tede/handle/tede/9212

Introduction: Pharmaceutical care is a practice model that allows direct interaction between the pharmacist and the patient and the healthcare team. This practice uses the pharmacotherapeutic follow-up as a tool in the identification and resolution of Drug Related Problems, which can contribute to rational drug use and collaborate with achieving positive clinical outcomes that minimize the physical and psychosocial impact that chronic diseases and their treatment can promote the quality of life of patients. Objective: The aim of this study was to evaluate the impact of pharmaceutical care on quality of life and on clinical profile of patients with hypertension, assisted by the Family Health Strategy. Methods: Was conducted a longitudinal intervention study involving 29 patients with hypertension who were assisted by the Family Health Strategy of two Basic Health Units at the sanitary district north in the city of Goiânia - GO. They received pharmacotherapeutic follow-up for 12 months, through systematized, pre-schedule and documented home visits. Were included patients that had at least two of the following inclusion criteria: blood pressure greater than or equal to 140x90 mm ​​Hg, using three or more drugs, change in the therapeutic regimen two or more times in the last year , presence of co-morbidities, and history of non-adherence to antihypertensive therapy. Data collection was performed using follow-up pharmacotherapeutic reports, visits reports and form registration of clinical and laboratory parameters, “Mini Cuestionario de Calidad de Vida en Hipertensión Arterial” (Minichal) and Morisky-Green-Levine Questionnaire. The variables studied were the socio economic and demographic profile, clinical profile, lifestyle, Drug Related Problems, adherence to antihypertensive therapy and quality of life. For descriptive statistics were used mean, standard deviation and measures of absolute and relative frequency. For statistical tests were used the McNemar parametric test, odds ratio, and linear mixed models, generalized mixed models, linear mixed models. The threshold for statistical significance set at p <0.05, with a confidence interval of 95%.Results: The results showed that there was a reduction in the number of drug-related problem of security, increased self-reported adherence to antihypertensive treatment. There was improvement in quality of life related to the somatic manifestations domain and its correlation with the reduction in the number of drug-related problem of security. There was a significant reduction in abdominal circumference of female patients, there were found correlation between the quality of life for the somatic manifestations domain and the clinical outcomes of diastolic blood pressure, triglycerides and abdominal circumference. Just the diastolic blood pressure showed correlated with mental state domain of quality of life. There was a positive correlation between interventions directed to the patient related with the medications domain and the changes in the clinical results for fasting glucose. The life style domain presented correlation with systolic and diastolic blood pressure. Conclusions: The results showed that the pharmaceutical care reduced the number of security Drug Related Problems, improved quality of life related to the somatic manifestations domain. There was an increase in adherence to antihypertensive treatment declared by patients; however this did not influence the improvement of quality of life. Furthermore, the results revealed that there was a significant reduction in the women's measures abdominal circumference; that the pharmaceutical interventions directed to the patient influenced in the clinical results of fasting glucose, systolic and diastolic blood pressure; and that the changes observed in the clinical outcomes of diastolic blood pressure, triglycerides and abdominal circumference impacted on the quality of life related to the somatic manifestations.